United Therapeutics Corporation
UTHR
$556.82
-$5.27-0.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.10% | -1.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.10% | -1.16% | |||
| Cost of Revenue | 29.01% | 2.48% | |||
| Gross Profit | -5.63% | -1.69% | |||
| SG&A Expenses | -3.05% | 4.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.29% | 5.51% | |||
| Operating Income | -8.84% | -8.19% | |||
| Income Before Tax | -28.31% | 1.37% | |||
| Income Tax Expenses | -45.55% | -19.74% | |||
| Earnings from Continuing Operations | -24.54% | 7.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -24.54% | 7.56% | |||
| EBIT | -8.84% | -8.19% | |||
| EBITDA | -8.36% | -7.54% | |||
| EPS Basic | -24.89% | 8.80% | |||
| Normalized Basic EPS | -5.06% | -6.95% | |||
| EPS Diluted | -24.44% | 7.57% | |||
| Normalized Diluted EPS | -4.42% | -8.02% | |||
| Average Basic Shares Outstanding | 0.46% | -1.14% | |||
| Average Diluted Shares Outstanding | -0.21% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||